5-azacytidine

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma

PKC412 and 5-Azacytidine

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia